Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation

Purpose By incorporating major developments in genetics, ophthalmology, dermatology, and neuroimaging, to revise the diagnostic criteria for neurofibromatosis type 1 (NF1) and to establish diagnostic criteria for Legius syndrome (LGSS). Methods We used a multistep process, beginning with a Delphi method involving global experts and subsequently involving non-NF experts, patients, and foundations/patient advocacy groups. Results We reached consensus on the minimal clinical and genetic criteria for diagnosing and differentiating NF1 and LGSS, which have phenotypic overlap in young patients with pigmentary findings. Criteria for the mosaic forms of these conditions are also recommended. Conclusion The revised criteria for NF1 incorporate new clinical features and genetic testing, whereas the criteria for LGSS were created to differentiate the two conditions. It is likely that continued refinement of these new criteria will be necessary as investigators (1) study the diagnostic properties of the revised criteria, (2) reconsider criteria not included in this process, and (3) identify new clinical and other features of these conditions. For this reason, we propose an initiative to update periodically the diagnostic criteria for NF1 and LGSS

Algorithm for molecular diagnosis of the Neurofibromatosis NF1, NF2 and NF3 (Schwannomatosis)

Neuropathological evaluation of CNS tumors is increasingly dependent on molecular genetic tests for proper classification, prediction of biological behavior and patient management. The neurofibromatoses (NFs) consist of at least three autosomal dominant inherited disorders: neurofibromatosis type 1 (NF1), type 2 (NF2), and schwannomatosis (NF3). The molecular diagnosis is still difficult due to: 1) absence of hotspots in NF1/NF2 genes, 2) ≥50% of sporadic cases for NF1/NF2, 3) NF1 gene large size and the existence of several pseudogenes. NF3 the newly recognized form is poorly understood: 1) only 15% of cases are inherited, 2) is caused by concomitant loss of several tumor suppressor genes by a single mutational event, 3) the 2 predisposition genes (SMARCB1 and LZTR1) identified do not explain all cases. Our aim is to show the diagnostic algorithms for molecular genetic testing for the NFs. We have used segregation analysis of STRs, mutational screening by DNA sequencing and exome sequencing (WES).The analysis of a family with NF1 numerous patients revealed the at-risk haplotype in one on the unaffected probands and a recombination event in two individuals (one affected and one asymptomatic). In four out of 11 NF2 patients tree small novel germinal mutations (2 frameshift and 1 splice-site) and one partial deletion of the maternal NF2 copy were identified, as well as a loss of heterozygosity (LOH) in the fifth patient. Molecular analysis of four patients with NF3 showed no mutations in SMARCB1 gene. One of the patients with family history studied by WES, did not show alterations in the predisposing genes. Analysis of four of this patient´s tumors did not display the frequently observed LOH. Evaluation of abnormalities in these genes was performed using a diagnostic algorithm which depends on the type of NF, family history and sample availability.Fil: Luce, Leonela Natalia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; ArgentinaFil: Parma, Diana Lidia. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Genética y Biología Molecular; ArgentinaFil: Giliberto, Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; ArgentinaFil: Francipane, Liliana. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaFil: Ciavarelli, Patricia. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaFil: Szijan, Irena. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Genética y Biología Molecular; ArgentinaFil: Ferrer, Marcela. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaLXII Reunión Científica de la Sociedad Argentina de Investigación Clínica; LIII Reunión Anual de la Sociedad Argentina de Investigación Bioquímica y Biología Molecular; LXV Reunión Anual de la Sociedad Argentina de Inmunología; Reunión de la Sociedad Argentina de Andrología; XLVI Reunión Anual de la Sociedad Argentina de Biofísica ; XLIX Reunión Anual de la Sociedad Argentina de Farmacología Experimental; Reunión Anual de la Sociedad Argentina de Fisiología; Reunión de la Sociedad Argentina de Hematología y XXIX Reunión Anual de la Sociedad Argentina de ProtozoologíaArgentinaSociedad Argentina de Investigación ClínicaSociedad Argentina de investigación bioquímica y biología molecularSociedad Argentina de InmunologíaSociedad Argentina de AndrologíaSociedad Argentina de BiofísicaSociedad Argentina de Farmacología ExperimentalSociedad Argentina de FisiologíaSociedad Argentina de HematologíaSociedad Argentina de Protozoologí

Gene expression profiling of ErbB receptors and ligands in human meningiomas.

ErbB family receptors mediate major cellular functions implied in tumorigenesis, though their role in meningiomas was not thoroughly studied. Meningiomas represent 30% of primary cranial tumors, are mostly benign, and prevail in the second half of life. Tumor therapy requires information about molecular alterations, thus we studied expression of ErbB receptor and ligand genes by real-time RT-PCR in different meningioma grades. Receptors were overexpressed (ErbB1, ErbB2) or underexpressed (ErbB3, ErbB4). Ligands EGF, TGFA, AREG, DTR, BTD were underexpressed and the neuregulins were overexpressed or underexpressed. A strong ErbB1-ErbB2 correlation was found. These data might be useful for gene therapy.Journal ArticleResearch Support, Non-U.S. Gov'tinfo:eu-repo/semantics/publishe

Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome

Purpose: By incorporating major developments in genetics, ophthalmology, dermatology, and neuroimaging, to revise the diagnostic criteria for neurofibromatosis type 1 (NF1) and to establish diagnostic criteria for Legius syndrome (LGSS). Methods: We used a multistep process, beginning with a Delphi method involving global experts and subsequently involving non-NF experts, patients, and foundations/patient advocac